B2i Digital Featured Company_Jaguar Health Inc_Nasdaq JAGX_Logo White

Jaguar Health, Inc.

Jaguar Health, Inc. (Jaguar) (Nasdaq: JAGX) (and its family company Napo Pharmaceuticals (Napo) is a commercial-stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with GI distress, specifically overactive bowel, which includes symptoms such as chronic debilitating diarrhea, GI urgency, and GI incontinence.

Napo's main product is crofelemer (trade name Mytesi), an FDA-approved plant-based prescription drug for HIV-related diarrhea extracted from trees sustainably harvested in the Amazon rainforest. The most critical near-term catalysts are the comprehensive results of a pivotal phase 3 OnTarget trial, expected in Q1 2024, to expand Mytesi's label into the preventative treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy; and the generation of proof-of-concept (POC) data targeted in 2024 in support of potential early patient access in specific EU countries. The POC studies are aimed at expanding crofelemer into two rare disease indications: short bowel syndrome (SBS) and microvillus inclusion disease (MVID) with intestinal failure.

Nasdaq: JAGX
Jaguar Health - Investors & News: https://jaguarhealth.gcs-web.com/
Nasdaq Profile: https://www.nasdaq.com/market-activity/stocks/jagx
Headquarters: San Francisco, California

TALK TO MANAGEMENT

Jaguar Health, Inc. is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

All content on this page is accurate as of 01.16.23.

Jaguar Health At A Glance

Press Releases & Media Coverage

Social Media Updates

Investor Presentation

Stock Chart (Intraday)

Stock Chart (Historical)

Stock Detail

Lead Drug Candidate: Crofelemer

How Crofelemer Works

Jaguar/Napo Product Portfolio – Crofelemer Pipeline

Videos – Jaguar Health: Improving Lives

Global Market Growth Opportunities

2024 Critical Activities to Unlock Jaguar Health's Value Potential

Commercial Rights and Partnerships

Jaguar and Magdalena Biosciences Collaboration

Financial Summary

Analyst Coverage

A Deep and Seasoned Leadership Team

Lead Drug Candidate: Crofelemer

How Crofelemer Works

Jaguar/Napo Product Portfolio – Crofelemer Pipeline

Videos – Jaguar Health: Improving Lives

Global Market Growth Opportunities

2023 Critical Activities to Unlock Jaguar Health's Value Potential

Commercial Rights and Partnerships

Jaguar and Magdalena Biosciences Collaboration

Financial Summary

Analyst Coverage

A Deep and Seasoned Leadership Team

SEC Filings

Financials

Risks & Disclosures

Jaguar-Health-Logo-white

The Jaguar Health management and investor relations team are available to talk to current and potential investors. They're happy to answer your questions and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

• Directly hear the Jaguar Health story
• Ask your questions
• Submit the form below, and someone will get in touch with you as soon as possible

Note: Company management or its representative can only discuss and disclose information that is already available in the public domain. They will do their best to clarify such information to the extent permitted by securities law and industry regulations.